BioCentury

7:00 AM GMT, Aug 13, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Inform Genomics: SNPing side effects

Inform Genomics Inc. is developing its OnPART test to predict which cancer patients are most likely to have chemotherapy side effects and allow doctors to treat the unwanted effects earlier or change the chemotherapy regimens they had planned to use.

OnPART (Oncology Preferences And Risk of Toxicity) uses a chip to screen a patient's saliva against a network of SNPs associated with six common side effects of chemotherapy: nausea and vomiting, diarrhea, oral mucositis, fatigue, neuropathy and cognitive dysfunction.

The company's personalized approach includes a questionnaire for

Read the full 855 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.